PMV Pharmaceuticals (PMVP)

What Moves the Stock

1. 01Clinical trial data releases for PC14586 - interim efficacy/safety results from ongoing Phase 1/2 studies
2. 02FDA regulatory milestones - IND approvals, breakthrough therapy designations, or clinical hold notifications
3. 03Cash runway updates - quarterly burn rate and sufficiency of $108M cash position (10.76x current ratio suggests ~2-3 years runway)
4. 04Partnership announcements with major pharmaceutical companies for co-development or licensing
5. 05Competitive developments in p53-targeted oncology space from Roche, Novartis, or other precision oncology players
6. 06No current revenue - pre-commercial stage
7. 07Future revenue contingent on regulatory approval and commercialization of PC14586
8. 08Potential partnership/licensing agreements for pipeline assets

PMVP Chart

My Notes

• growth - Attracts speculative, high-risk-tolerance investors seeking asymmetric returns from binary clinical trial outcomes.
• Rising interest rates negatively impact PMVP through two channels: (1) Higher discount rates compress the present value of distant future…
• Watch on earnings: PC14586 clinical trial data releases - objective response rates, progression-free survival, and safety profile in p53-mutant solid tumors, Quarterly cash burn rate and runway projections relative to next major clinical milestone, FDA regulatory feedback and potential breakthrough therapy designation status.